Hansa Biopharma AB's Total Assets for the quarter that ended in Mar. 2024 was kr830.6 Mil.
During the past 12 months, Hansa Biopharma AB's average Total Assets Growth Rate was 35.80% per year.
During the past 3 years, the average Total Assets Growth Rate was 71.20% per year.
During the past 5 years, the average Total Assets Growth Rate was 33.30% per year.
During the past 10 years, the average Total Assets Growth Rate was 17.10% per year.
During the past 13 years, Hansa Biopharma AB's highest 3-Year average Total Assets Growth Rate was 71.20%. The lowest was -4.00%. And the median was 5.70%.
The historical data trend for Hansa Biopharma AB's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Hansa Biopharma AB's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansa Biopharma AB (OSTO:HNSA) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Hansa Biopharma AB's Asset Turnover for the quarter that ended in Mar. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Hansa Biopharma AB Total Assets Related Terms
Thank you for viewing the detailed overview of Hansa Biopharma AB's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Hansa Biopharma AB (OSTO:HNSA) Business Description
Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OSTO:HNSA has been successfully added to your 